Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients

 
• By Mary Jo Laffler
  
Approved check mark
Takeda's Livtencity was approved by FDA for CMV in transplant patients
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip